Is ATOS SE(Euronext) a good stock to invest in recently?

**Atossa Therapeutics (ATOS) does not appear to be a good investment candidate at the moment**. Here's why: 1. **Recent Performance**: The stock's closing price on December 31, 2024, was €1.06, which represents a 1.28% decrease from the previous day. This recent decline suggests negative market sentiment. |Ticker|Name|Date|Closing Price|Trading Volume|code|market_code| |---|---|---|---|---|---|---| |SE.N|Sea|20241231|106.1|1904072|SE|169| |ATOS.O|Atossa Therapeutics|20241231|0.9441|1155439|ATOS|186| 2. **Technical Indicators**: The stock's Moving Average Convergence Divergence (MACD) is slightly negative at -0.01, and its Relative Strength Index (RSI) is at 26.83, indicating it may be oversold. However, the stock is trading below its 5-Day, 10-Day, and 20-Day moving averages, which could be seen as a bearish signal. |Ticker|Name|Date|Boll|RSI|KDJ|MACD|code|market_code| |---|---|---|---|---|---|---|---|---| |ATOS.O|Atossa Therapeutics|20241231|1.0927|26.8346|23.8840|-0.0088|ATOS|186| 3. **Moving Averages**: The stock is also trading below its 30-Day, 50-Day, and 60-Day moving averages, which further supports the bearish outlook. Additionally, the 120-Day, 200-Day, and 250-Day moving averages are higher than the current stock price, suggesting a long-term downward trend. |Ticker|Name|Date|Moving Average|code|market_code| |---|---|---|---|---|---| |ATOS.O|Atossa Therapeutics|20241231|0.9979|ATOS|186| 4. **Financial Performance**: The company reported a negative Diluted EPS of €0.06 for the most recent quarter, which is a red flag for profitability. |Ticker|Name|Date|Total Revenue|Diluted EPS|code|market_code| |---|---|---|---|---|---|---| |ATOS.O|Atossa Therapeutics|2023 Q4|0||ATOS|186| |ATOS.O|Atossa Therapeutics|2024 Q1||-0.05|ATOS|186| |ATOS.O|Atossa Therapeutics|2024 Q2||-0.05|ATOS|186| |ATOS.O|Atossa Therapeutics|2024 Q3||-0.06|ATOS|186| 5. **Recent News**: While Atossa Therapeutics has announced some positive developments in their research related to (Z)-endoxifen, such as presenting groundbreaking research findings at the 2024 San Antonio Breast Cancer Symposium, these announcements do not necessarily translate into immediate positive stock performance. The company's Phase 2 KARISMA-Endoxifen trial showed promising results in reducing mammographic breast density, but the 2 mg dose was associated with higher rates of adverse events. This could be a concern for investors regarding the drug's safety and potential market acceptance. 6. **Market Sentiment**: The overall market sentiment appears cautious, as evidenced by the stock trading below its key moving averages and the recent negative price movement. Investors should closely monitor any updates from the company, including the outcomes of the ongoing trials and the potential for regulatory approvals that could impact the stock's trajectory. In conclusion, the current indicators and recent news suggest that ATossa Therapeutics is not a good investment candidate at the moment. Investors should exercise caution and consider these factors before making an investment decision.